发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatment. 揭开癌症治疗中的致癌驱动因素与免疫疗法疗效之间的联系。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0190
Hiba Mechahougui, Alex Friedlaender
{"title":"Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatment.","authors":"Hiba Mechahougui, Alex Friedlaender","doi":"10.2217/imt-2023-0190","DOIUrl":"10.2217/imt-2023-0190","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"267-271"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathological findings directing immunotherapy in renal cell carcinomas. 引导肾细胞癌免疫疗法的病理学发现。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI: 10.2217/imt-2023-0249
Fadime Eda Gökalp Satıcı, Yasemin Yuyucu Karabulut
{"title":"Pathological findings directing immunotherapy in renal cell carcinomas.","authors":"Fadime Eda Gökalp Satıcı, Yasemin Yuyucu Karabulut","doi":"10.2217/imt-2023-0249","DOIUrl":"10.2217/imt-2023-0249","url":null,"abstract":"<p><p>Tweetable abstract Immunotherapy options in RCC treatment are increasing day by day. In pursuit of this objective, we have explored the role of pathology throughout the process, from the development to the implementation of immunotherapy in this paper.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"199-204"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment. 摘要：银屑病中的赛妥珠单抗 pegol，包括结构特点、药代动力学和治疗。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-02-06 DOI: 10.2217/imt-2023-0058
Michio Tokuyama, Tomotaka Mabuchi
{"title":"Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment.","authors":"Michio Tokuyama, Tomotaka Mabuchi","doi":"10.2217/imt-2023-0058","DOIUrl":"10.2217/imt-2023-0058","url":null,"abstract":"<p><p>Psoriasis pathogenesis involves TNF-α, IL-23 and IL17, against which biologics have been highly effective. Among the five TNF-α inhibitors available for psoriasis, namely infliximab, adalimumab, etanercept, golimumab and certolizumab pegol (CZP), CZP has a unique mechanism of action due to its structure. As CZP lacks the Fc region, it does not cross the placenta and can be safely used in pregnant women. Its PEGylated nature allows for longer distribution time in tissues, potentially leading to a longer-lasting effect compared with other TNF-α inhibitors. In clinical trials, the efficacy of CZP on psoriasis skin symptoms and joint symptoms was comparable to other TNF-α inhibitors, with no discernible differences in safety profiles.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"273-285"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events. 评估夏尔森综合症指数在预测免疫检查点抑制剂相关不良事件方面的有效性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-30 DOI: 10.2217/imt-2023-0270
İlknur Deliktaş Onur, Emel Mutlu, Elif Sertesen, Tuğba Önder, Ayşe Ocak Duran, Mevlüde İnanç
{"title":"Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events.","authors":"İlknur Deliktaş Onur, Emel Mutlu, Elif Sertesen, Tuğba Önder, Ayşe Ocak Duran, Mevlüde İnanç","doi":"10.2217/imt-2023-0270","DOIUrl":"10.2217/imt-2023-0270","url":null,"abstract":"<p><p><b>Aims:</b> Our study aimed to evaluate the effectiveness of the Charlson Comorbidity Index (CCI) in predicting immune-related adverse events (irAEs) in solid tumor patients receiving immunotherapy. <b>Patients & methods/materials:</b> The CCI score at the time of initiation of immunotherapy was calculated in 164 solid tumor patients receiving immunotherapy and the correlation between the CCI score and immune toxicity was evaluated. <b>Results:</b> A significant relationship was found between CCI score and irAEs in lung cancer and renal cell cancer patients. In malignant melanoma, no significant relationship was found between the CCI score and the occurrence of irAEs. <b>Conclusion:</b> We argue that CCI can be used to predict irAEs, but we believe that a specific comorbidity index that includes autoimmune diseases should be developed.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"295-303"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer. 治疗三阴性乳腺癌的新辅助免疫疗法的当前和未来趋势。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2022-0277
Ramon Andrade de Mello, Kátia Roque Perez, Thais Pérez Vazquez
{"title":"Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer.","authors":"Ramon Andrade de Mello, Kátia Roque Perez, Thais Pérez Vazquez","doi":"10.2217/imt-2022-0277","DOIUrl":"10.2217/imt-2022-0277","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) comprises 15-20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"257-266"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab. 免疫检查点抑制剂疗法诱发的类固醇依赖性多关节炎成功治愈了bimekizumab。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-24 DOI: 10.2217/imt-2023-0252
Robin Springer, Kristin Lange, Bernhard Homey, Stephan Meller, Harm-Henning Lindhof
{"title":"Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab.","authors":"Robin Springer, Kristin Lange, Bernhard Homey, Stephan Meller, Harm-Henning Lindhof","doi":"10.2217/imt-2023-0252","DOIUrl":"10.2217/imt-2023-0252","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are an integral part of modern-day cancer therapy. Along with a greatly improved antitumor response come a number of immune-related adverse events (irAEs), musculoskeletal irAEs rank among the less frequent manifestations. The mechanisms behind these events are poorly understood, and so far clear guidelines for therapeutic management beyond treatment with glucocorticosteroids are lacking. We present the case of a 72-year-old patient who developed a severe ICI-induced polyarthritis that could not be controlled by glucocorticosteroids. We initiated an immunomodulating therapy with the IL-17A/F/AF-inhibitor bimekizumab, which lead to a full clinical and sonographic remission.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"287-293"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies. 两项研究旨在了解阿伐卡塔哌啶是否对地理萎缩患者有效且安全：GATHER1 和 GATHER 2 研究的通俗摘要。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-25 DOI: 10.2217/imt-2023-0274
Glenn J Jaffe, Arshad M Khanani
{"title":"Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies.","authors":"Glenn J Jaffe, Arshad M Khanani","doi":"10.2217/imt-2023-0274","DOIUrl":"10.2217/imt-2023-0274","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of two publications. One publication is about the GATHER1 study, which was published in the journal <i>Ophthalmology</i> in 2021. The other publication is about the GATHER2 study, which was published in the journal <i>The Lancet</i> in 2023. Both studies included adult participants with geographic atrophy (GA). GA is an advanced form of dry age-related macular degeneration (dry AMD). The participants in both studies each received treatment in one of their eyes. In both studies, the researchers wanted to learn if avacincaptad pegol (ACP) could help to slow the worsening of the participants' GA over time.</p><p><strong>What were the results?: </strong>In these studies, the researchers found that ACP helped to slow the growth of the GA area in the participants' eyes compared with a sham injection. Participants who received ACP had a similar ability to read differently sized letters on a chart 1 year after treatment compared with participants who received no ACP through a sham injection. In the GATHER1 study, none of the participants had serious medical problems in the eye that received the injection. In the GATHER2 study, 2 out of 225 participants (less than 1%) who received ACP had serious medical problems in the eye that received the injection. In the group who received the sham injection, 2 out of the 222 participants (less than 1%) had serious medical problems in the eye that received the sham injection.</p><p><strong>What do the results mean?: </strong>ACP could be a treatment option for people with GA. The results from several studies are needed to decide which treatments work best and are safest. Other studies may provide new information or different results. Always talk to a doctor before making any treatment changes.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"205-221"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. 透视：将ctDNA纳入《实体瘤反应评估标准1.1》，用于II期免疫疗法临床试验。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2023-0184
Tulay Kus, Irfan Cicin
{"title":"A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials.","authors":"Tulay Kus, Irfan Cicin","doi":"10.2217/imt-2023-0184","DOIUrl":"10.2217/imt-2023-0184","url":null,"abstract":"<p><p>A consensus guideline, iRECIST, was developed by the Response Evaluation Criteria in Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in cancer immunotherapy trials. iRECIST was designed to separate pseudoprogression from real progression. However, this is not the only ambiguous situation. In clinical immunotherapy trials, stable disease may reflect three tumor responses, including real stable disease, progressive disease and responsive disease. The prediction of a \"<i>true complete/partial response\"</i> is also important. Much data has accumulated showing that ctDNA can guide decisions at this point; thus, integrating ctDNA into the RECIST 1.1 criteria may help to distinguish a true tumor response type earlier in patients treated with immunotherapy; however, prospectively designed validation studies are needed.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"319-329"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma. pembrolizumab与白蛋白结合型紫杉醇和奈达铂联合治疗晚期食管鳞状细胞癌的有效性和安全性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2023-0188
Fang Yan, Longpei Chen, Mingzhen Ying, Jie Li, Qiang Fu
{"title":"Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma.","authors":"Fang Yan, Longpei Chen, Mingzhen Ying, Jie Li, Qiang Fu","doi":"10.2217/imt-2023-0188","DOIUrl":"10.2217/imt-2023-0188","url":null,"abstract":"<p><p><b>Objective:</b> This research aimed to assess the efficacy and safety of pembrolizumab (PBL) combined with albumin-bound paclitaxel (ab-Pac) and nedaplatin (NDP) for advanced esophageal squamous cell carcinoma (ESCC). <b>Methods:</b> A total of 47 ESCC patients were administered PBL or NDP on day 1 and ab-Pac on days 1 and 8, every 21 days for one cycle. Tumor and toxicities were evaluated every two cycles and every cycle, respectively. <b>Results:</b> The objective response rate was 68.1% and the disease control rate was 100%. The median follow-up was 16.7 months; median progression-free and overall survival were 12.6 and 19.9 months, respectively. <b>Conclusion:</b> The combination of PBL with ab-Pac and NDP proved to be an effective and safe treatment regimen for advanced ESCC.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"305-317"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma. SAFFRON-103：西曲替尼联合替赛珠单抗治疗抗PD-(L)1难治/耐药晚期黑色素瘤的Ib期研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2023-0130
Xuan Wang, Hongming Pan, Jiuwei Cui, Xiao Chen, Won-Hee Yoon, Matteo S Carlino, Xin Li, Hui Li, Juan Zhang, Jingchao Sun, Jun Guo, Chuanliang Cui
{"title":"SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma.","authors":"Xuan Wang, Hongming Pan, Jiuwei Cui, Xiao Chen, Won-Hee Yoon, Matteo S Carlino, Xin Li, Hui Li, Juan Zhang, Jingchao Sun, Jun Guo, Chuanliang Cui","doi":"10.2217/imt-2023-0130","DOIUrl":"10.2217/imt-2023-0130","url":null,"abstract":"<p><p><b>Aim:</b> Investigate TKI sitravatinib plus anti-PD-1 antibody tislelizumab in patients with unresectable/advanced/metastatic melanoma with disease progression on/after prior first-line anti-PD-(L)1 monotherapy. <b>Methods:</b> Open-label, multicenter, multicohort study (NCT03666143). Patients in the melanoma cohort (N = 25) received sitravatinib once daily plus tislelizumab every 3 weeks. The primary end point was safety and tolerability. <b>Results:</b> Treatment-emergent adverse events (TEAEs) occurred in all patients, with ≥grade 3 TEAEs in 52.0%. Most TEAEs were mild-or-moderate in severity, none were fatal, and few patients discontinued treatment owing to TEAEs (12.0%). Objective response rate was 36.0% (95% CI: 18.0-57.5). Median progression-free survival was 6.7 months (95% CI: 4.1-not estimable). <b>Conclusion:</b> Sitravatinib plus tislelizumab had manageable safety/tolerability in patients with anti-PD-(L)1 refractory/resistant unresectable/advanced/metastatic melanoma, with promising antitumor activity. <b>Clinical Trial Registration</b>: NCT03666143 (ClinicalTrials.gov).</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"243-256"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信